TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~* Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.~* Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (ie, a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study.~* age \> 18~* Karnofsky performance status \> 60%~* Measurable disease on clinical exam or by RECIST criteria~* One prior platinum-based systemic chemotherapy regimen for advanced disease is allowed but not required. Chemotherapy administered as a radiosensitizer in conjunction with primary radiotherapy is not considered a systemic chemotherapy regimen and is also allowed. Patients eligible for a higher priority study will be excluded.~* Life expectancy \> 6 weeks~* Peripheral neuropathy ≤ Grade 2 by CTC 3.0 criteria~* Women of child-bearing potential must have a negative pregnancy test~* Adequate hematopoietic function defined as: ANC ≥ 1500/mm3; Platelets ≥ 100,000/mm3; Hemoglobin ≥ 8 g/dL.~* Adequate renal and hepatic function defined as: Bilirubin ≤ 1.5 times upper limit of normal (ULN); SGOT ≤ 2.5 times ULN; Alkaline phosphatase ≤ 2.5 times ULN; Creatinine ≤ 2 times ULN.~Exclusion Criteria~* Patient has hypersensitivity to bortezomib, boron or mannitol.~* Female subject is pregnant or breast-feeding.~* Patient has received other investigational drugs with 14 days before enrollment~* Serious medical or psychiatric illness likely to interfere with participation in this clinical study.~* Prior treatment with CAMPTOSAR or VELCADE~* More than one prior treatment for metastatic disease.~* Concurrent uncontrolled illness~* Ongoing or active infection~* History or active secondary cancer within the last 5 years, except for superficial basal cell skin cancers~* Psychiatric illness or social situation that would preclude study compliance.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lipids Profile in Primary Hyperparathyroidism

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with primary hyperparathyroidism~Exclusion Criteria:~* pregnant women~* patient taking hypolipidemic drugs~* patients with known cardiovascular, peripheral or cerebral atherosclerotic disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Constitution of a Biological Cohort Following Bone Marrow Sampling From MDS or AML Patients and Age-matched Healthy Donors

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with diagnosed myelodysplasia or acute myeloid leukemia (study place: ICLN) - Specific to the cases cohort~* Age-matched healthy donors undergoing a cardiovascular surgery - Specific to the control cohort~* Signed written informed consent form~* Patient affiliated to a social security regimen or beneficiary of the same~Exclusion Criteria:~* Medical history of hematological disorders~* Thrombocytopenia, anemia...~* Patient under guardianship or deprived of his liberty or any condition that may affect the patient's ability to understand and sign the informed consent (art. L.1121-6, L.112-7, L.1211-8, L.1211-9)~* Pregnant or breastfeeding women~* Refusing participation

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Acute Myeloid Leukemia patients (Type: None): For diagnosis purpose, bone marrow sampling is performed for acute myeloid leukemia patients. 2 milliliters of this sample will be collected and analysed for the COSMOS study.
- Healthy donors (Type: None): Healthy donors are patients undergoing cardio-vascular surgery for their usual support. During this surgery, 2 milliliters of the bone marrow will be collected, and analysed for the COSMOS study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Health Intervention to Prevent Depression Hepatitis C Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with Hepatitis C and prescribed IFN-α~* Ability to understand and willingness to provide written informed consent.~* Willing to provide contact information.~* Medical clearance with protocol-defined stress testing (in accordance with American College of Sports Medicine (ACSM) guidelines) from protocol approved medical personnel. Details of guidelines and related testing protocol are provided in the study Manual of Procedures.~* Able to comprehend and communicate in English.~Exclusion Criteria:~* Have a medical condition contraindicating exercise participation~* Are currently physically active - defined as moderate intensity physical activity on 3 or more days per week for the last month~* Have been diagnosed with current Major Depressive Disorder or are currently receiving antidepressant medication treatment (including SSRIs and SNRIs)~* Currently considered a high suicide risk and/or high risk for being unable to complete the study due to the need for psychiatric hospitalization, suicide attempts or suicidality, significant self-mutilation, or other self-injurious or destructive behavior based on the judgment of the site PI, medical personnel, or designee.~* Pregnancy.~* Current psychotic disorder. Other comorbid psychiatric diagnosis that, in the investigator's judgment, will pose a safety issue or make it difficult for the participant to understand or complete the intervention.~* Anticipated circumstances over the 6-month course of the trial that would render the participant unlikely to complete the study in the judgment of the PI or designee.~* Any reason not listed herein yet, determined by the PI, medical personnel, or designee that constitutes good clinical practice and that would in the opinion of the PI, medical personnel, or designee make participation in the study hazardous.~* Are currently enrolled in another research study, and participation in that study contraindicates participation in the current study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Health Education (Type: ACTIVE_COMPARATOR): Participants will three attend heath education sessions per week for 26 weeks.
- Exercise (Type: EXPERIMENTAL): Participants will engage in a public health dose of moderate-to-vigorous aerobic exercise for 26 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Intraoperative Ultrasound in Laparoscopic or Robotic Myomectomy Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Premenopausal and nonpregnant~2. Advised to undergo laparoscopic or robotic myomectomy by their provider~3. Documented imaging with transvaginal ultrasound or pelvic MRI within the past year, which accurately and within reason documents the location and number of leiomyomas present within the uterus~4. If deemed necessary by the provider, must have a pelvic MRI prior to surgery that states there are no concerning findings for malignancy~5. Must be eligible to undergo laparoscopic surgery and willing to present for clinic and imaging follow up during the 6 months following myomectomy~6. Must understand and voluntarily sign an informed consent form.~Exclusion Criteria:~1. Appearance of uterus concerning for malignancy on pelvic MRI~2. Current pregnancy~3. Any contraindication to laparoscopic or robotic surgery~4. Treatment with gonadotropin-releasing hormone (GnRH) analogs in the past 36 months

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Without Ultrasound (Type: NO_INTERVENTION): Laparoscopic or robotic myomectomy will be performed without aid of intraoperative contact ultrasonography
- With Ultrasound (Type: EXPERIMENTAL): Laparoscopic or robotic myomectomy will be performed with aid of intraoperative contact ultrasonography

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Human Factors Actual-Use Clinical Protocol

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>/= 21 and \< 50 years.~2. Planned laparoscopic hysterectomy or myomectomy.~3. Tissue specimen is \<11 cm in maximum diameter based on standard preoperative assessment.~4. Pre-operative evaluation which may include imaging, cervical cancer screening, and endometrial biopsy has been completed.~5. Signed informed consent.~6. Willing to adhere to protocol requirements and complete follow-up.~Exclusion Criteria:~1. Subject is post-menopausal, defined as amenorrhea \>12 months in the absence of ovulation suppression.~2. Known or suspected malignancy of gynecological origin as determined by standard clinical practice.~3. Candidate for en bloc tissue removal, for example through the vagina or via a mini-laparotomy incision.~4. Hemoglobin \< 8 g/dl within 30 days prior to surgery.~5. Subject has a current history of undiagnosed genital bleeding.~6. Subject has an implanted electronic device where use of radiofrequency (RF) energy would be contraindicated (e.g., pacemaker, internal defibrillator).~7. Medical condition, surgical history, or intra-operative findings, which in the option of the investigator, precludes utilization of the Eximis CS System.~8. Known allergy to polyurethane, polyethylene, thermoplastic fluoropolymer and/or chlorinated polyvinyl chloride.~9. Concurrent participation in another therapeutic or interventional clinical trial with investigational pharmaceutical agent(s) or medical device(s) that could impact evaluation of this study as determined by the Investigator.~10. Inability to comply with the study procedures or follow-up in the opinion of the investigator.~11. Subject is pregnant.~12. Intraoperative Exclusion: Abdominal wall thickness at the umbilicus incision site is \> 8 cm.

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Study Arms:
- Human Factors Actual Use (Type: EXPERIMENTAL): Confirm device use safety and effectiveness of the Eximis CS (Contained Segmentation) System in actual use

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacogenetics of SGLT2 Inhibitors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Of Amish descent~* Age 21 or older~* BMI 18-40 kg/m2~Exclusion Criteria:~* Known allergy to canagliflozin~* History of diabetes, random glucose greater than 200 mg/dL, or HbA1c greater than or equal to 6.5%~* Currently taking diuretics, antihypertensive medication, uric acid lowering medications, or other medication that the investigator judges will make interpretation of the results difficult~* Significant debilitating chronic cardiac, hepatic, pulmonary, or renal disease or other diseases that the investigator judges will make interpretation of the results difficult or increase the risk of participation~* Seizure disorder~* Positive urine human chorionic gonadotropin (hCG) test or known pregnancy within 3 months of the start of the study~* Estimated glomerular filtration rate less than 60 mL/min~* Currently breast feeding or breast feeding within 3 month of the start of the study~* Liver function tests greater than 2 times the upper limit of normal~* Hematocrit less than 35%~* Currently symptomatic for urinary tract or yeast infection or history of two or more urinary tract or yeast infections in the past 12 months.~* Abnormal thyroid stimulating hormone (TSH)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Wild type genotype (Type: ACTIVE_COMPARATOR): Research subjects with wild type genotypes at three candidate genes encoding sodium-dependent glucose transporter-3, sodium-dependent glucose transporter-4, and glucose transporter-9 (abbreviated as SLC5A4, SLC5A9, SLC2A9, respectively) will be studied before and after canagliflozin treatment.
- Nonsense mutation in SLC5A4 (Type: EXPERIMENTAL): Research subjects who are homozygous for nonsense mutation in SLC5A4 (sodium-dependent glucose transporter-3) will be studied before and after canagliflozin treatment.
- Nonsense mutation in SLC5A9 (Type: EXPERIMENTAL): Research subjects who are homozygous for nonsense mutation in SLC5A9 (sodium-dependent glucose transporter-4) will be studied before and after canagliflozin treatment.
- Missense variant in SLC2A9 (Type: EXPERIMENTAL): Research subjects who are homozygous for nonsynonymous variant in glucose transporter-9 (SLC2A9) will be studied before and after canagliflozin treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Able to provide informed consent~* Diagnosed with moderate to severe rheumatoid arthritis for at least 6 months~* Active RA with at least 3 swollen and tender joints~* Failure to respond to a combination treatment of adalimumab and methotrexate (must have taken combination at least 3 months) or loss of a satisfactory response to the combination of adalimumab and methotrexate, which was taken for at least 6 months (if currently taking adalimumab must complete 2 weeks without it prior to starting study drug)~* Negative for hepatitis B and C~* Negative serum and urine pregnancy tests before starting study~* currently taking (stable dose) 15 mg methotrexate weekly for at least 8 weeks/has been taking methotrexate for at least 12 weeks total - lower dose of 10 mg per week is permitted with documented intolerability~* Normal chest X-ray within 3 months~* Negative testing for tuberculosis (TB)~Exclusion Criteria:~* Class IV RA (wheel-chair or bed-bound)~* Significant concurrent medical conditions, including: (uncontrolled type 1 diabetes, poorly controlled type 2 diabetes, symptomatic heart failure, myocardial infarction in past year, history of unstable angina within past year, uncontrolled hypertension, severe chronic pulmonary disease, major chronic inflammatory or connective tissue disease other than RA, Multiple sclerosis, active malignancy, or history of cancer, alcoholic hepatitis or history of alcoholic liver disease)~* Other inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Etanercept (Type: EXPERIMENTAL): Participants received etanercept 50 mg administered subcutaneously once a week with methotrexate for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Trial of Sonoelastography for Planning Tumor-targeted Prostate Biopsy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 years of age or older.~2. Serum PSA between 4 and 10 ng/mL.~3. A diagnosis of prostate cancer based on extended (twelve core) random prostate biopsy within three months prior to study entry.~4. Clinically localized prostate carcinoma i.e. TNM stage T2c or less.~5. The patient has elected to undergo radical prostatectomy to treat the prostate carcinoma.~6. The patient consents to undergo a diagnostic transrectal ultrasound of the prostate with elastography.~Exclusion Criteria:~1. Any contraindication to transrectal ultrasonography, including prior anorectal surgery, inflammatory bowel disease, rectal fistula, or fissure-in-ano.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sonoelastography (Type: EXPERIMENTAL): Sonoelastography is an imaging technology predicated on reproducible differences in the backscattered ultrasound signal produced by compression of tissues of varying stiffness.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study to Determine if Giving Intravenous Fish Oil Helps Children With Liver Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical evidence of parenteral nutrition associated cholestasis~* Direct bilirubin greater or equal to 2 mg/dL on 2 consecutive measurements~* Expected parenteral nutrition course greater than 30 days~* Acquired or congenital gastrointestinal disease~* \> 2 weeks of age and \< 18 years of age~* \> 60% calories from parenteral nutrition~* Failed standard therapies to prevent progression of liver disease (Actigal, cyclic parenteral nutrition, avoidance of overfeeding, reduction/removal of copper from parenteral nutrition if elevated my laboratory analysis, advancement of enteral feeds)~Exclusion Criteria:~* Inborn errors of metabolism~* Extracorporeal Membrane Oxygenation~* Seafood, egg, or Omegaven allergy~* Documented case of liver disease other than Parenteral Nutrition Associated Cholestasis~* Hemorrhagic disorder~* Anticoagulant therapy~* Hemodynamically unstable or in shock~* Comatose state~* Stroke, pulmonary embolism, recent myocardial infarction~* Diabetes~* Fatal chromosomal disorder~* Enrollment in any other clinical trial involving an investigational agent~* Patient, parent, or legal guardians unable or unwilling to give consent~* Patient expected to be weaned from parenteral nutrition in 30 days~* unable to tolerate necessary monitoring~* Patient requiring aspirin or toradel or motrin~* Patient requiring dialysis

- Gender: ALL
- Minimum Age: 2 Weeks
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Omegaven (Type: EXPERIMENTAL): 0.5 g/kg/d IV x 2 days, then 1 g/kg/d IV for 24 weeks or until parenteral nutrition discontinuation, death or transplant, whichever comes first. Subjects are eligible to restart Omegaven should they re-satisfy inclusion/exclusion criteria.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Sedation Versus General Anesthesia in Patients Undergoing Minor Gynecologic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients undergoing second trimester abortions:~* Pregnancy: 12-24 weeks gestational size~* ASA PS I and II~* No history of diabetes mellitus, GERD or sleep apnea~* Age: \> 18 years of age~* Fluent in English~Exclusion Criteria:~* ASA PSIII, Emergency surgery~* Pregnancy: \> 24 weeks gestational size~* Age: \< 18 years of age~* Diabetes mellitus~* Gastroesophageal reflux disease~* Hiatal hernia~* Obstructive sleep apnea~* Coagulopathy~* Chronic pain syndromes~* Chronic opioid dependency~* Alcohol or illicit drug abuse~* BMI: \> 35Kg/m2~* Allergy to study protocol drugs~Drop out criteria:~* Subjects withdrawal of consent.~* Subjects who experience massive bleeding intraoperatively, will be excluded from the final data analysis

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Deep Sedation (Type: ACTIVE_COMPARATOR): Deep sedation
- General Anesthesia (Type: OTHER): Administration of general anesthesia. Propofol given IV, succinylcholine and rocuronium given IV and Sevoflurane via the endotracheal tube.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility